Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13. doi: 10.1073/pnas.1111840108. Epub 2011 Nov 8.

2.

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, Lawrenson K.

Lab Invest. 2013 May;93(5):528-42. doi: 10.1038/labinvest.2013.41. Epub 2013 Mar 4.

3.

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.

Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y.

Breast Cancer Res. 2001;3(4):253-63. Epub 2001 Apr 2.

4.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
5.

IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.

Pavan S, Olivero M, Corà D, Di Renzo MF.

Eur J Cancer. 2013 Mar;49(4):964-73. doi: 10.1016/j.ejca.2012.09.024. Epub 2012 Oct 15.

PMID:
23079474
6.
7.

A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.

Andrews P, Zhao X, Allen J, Li F, Chang M.

Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. Epub 2007 Apr 20.

PMID:
17447067
8.

Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.

Schöndorf T, Neumann R, Benz C, Becker M, Riffelmann M, Göhring UJ, Sartorius J, von König CH, Breidenbach M, Valter MM, Hoopmann M, Di Nicolantonio F, Kurbacher CM.

Recent Results Cancer Res. 2003;161:111-6.

PMID:
12528803
9.

The clinical relevance of cancer cell lines.

Gillet JP, Varma S, Gottesman MM.

J Natl Cancer Inst. 2013 Apr 3;105(7):452-8. doi: 10.1093/jnci/djt007. Epub 2013 Feb 21.

10.

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.

Sandercock AM, Rust S, Guillard S, Sachsenmeier KF, Holoweckyj N, Hay C, Flynn M, Huang Q, Yan K, Herpers B, Price LS, Soden J, Freeth J, Jermutus L, Hollingsworth R, Minter R.

Mol Cancer. 2015 Jul 31;14:147. doi: 10.1186/s12943-015-0415-0.

11.
12.

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.

Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M.

PLoS One. 2013 Oct 23;8(10):e77232. doi: 10.1371/journal.pone.0077232. eCollection 2013.

13.

[Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].

Zhao D, Zhang W, Li XG, Wang XB, Zhang LF, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.

Zhonghua Fu Chan Ke Za Zhi. 2011 Mar;46(3):193-8. Chinese.

PMID:
21575453
14.
15.

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I.

Eur J Cardiothorac Surg. 2011 Jul;40(1):e29-33. doi: 10.1016/j.ejcts.2011.02.010. Epub 2011 Mar 21.

PMID:
21420313
16.

Multidrug-resistant gene expression in small-cell lung cancer.

Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG.

Am J Clin Oncol. 1997 Aug;20(4):398-403.

PMID:
9256898
17.

Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.

Li L, Luan Y, Wang G, Tang B, Li D, Zhang W, Li X, Zhao J, Ding H, Reed E, Li QQ.

Int J Mol Med. 2004 Aug;14(2):257-64.

PMID:
15254775
18.

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H.

Mol Cancer. 2009 Jun 8;8:34. doi: 10.1186/1476-4598-8-34.

19.

Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice.

Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T.

Drug Metab Dispos. 2010 Mar;38(3):526-33. doi: 10.1124/dmd.109.030668. Epub 2009 Dec 9.

20.

Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.

Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH.

Clin Cancer Res. 1997 Jan;3(1):115-22.

Supplemental Content

Support Center